<DOC>
	<DOC>NCT02094300</DOC>
	<brief_summary>The Zenith® Dissection Clinical Trial is a clinical trial approved by US FDA to study the safety and effectiveness of the Zenith® Dissection Endovascular System in the treatment of patients with aortic dissection.</brief_summary>
	<brief_title>Zenith® Dissection Endovascular System</brief_title>
	<detailed_description />
	<criteria>Branch vessel obstruction/compromise Periaortic effusion/hematoma Resistant hypertension Persistent pain/symptoms Transaortic growth &gt;5 mm within 3 months Transaortic diameter &gt;40 mm. Age &lt;18 years; Other medical condition (e.g., cancer, congestive heart failure) that may cause the patient to be noncompliant with the protocol, confound the results, or is associated with limited life expectancy (i.e., less than 2 years) Pregnant, breastfeeding, or planning on becoming pregnant within 24 months; Unwilling or unable to comply with the followup schedule Inability or refusal to give informed consent Simultaneously participating in another investigative device or drug study. (The patient must have completed the primary endpoint of any previous study at least 30 days prior to enrollment in this study.) Additional medical restrictions as specified in the Clinical Investigation Plan, or Additional anatomical restrictions as specified in the Clinical Investigation Plan.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Aorta</keyword>
	<keyword>Thoracic</keyword>
	<keyword>Aortic dissection</keyword>
	<keyword>Rupture</keyword>
	<keyword>Type B</keyword>
	<keyword>DeBakey type III</keyword>
	<keyword>Endovascular</keyword>
</DOC>